Conjugated Estrogens

Brand Name Manufacturers

Premarin by Wyeth-Ayerst

Generic Manufacturers

None

Pharmacology

Sodium salts of estrogen sulfates. Apparently acts on receptors the sameas endogenous estrogen.

Delivery

0.3mg, 0.625, 0.9, 1.25, 2.5mg tablets

Typical dosage

Pre-op Oral 1.25-7.5mg/day
Post-op Oral 0.625-3.75mg/day

Availability

Approved by U.S. FDA

Indications

Estrogen replacement therapy in females.Treatment of selected breast and prostate cancers.

Contraindications

Active blood clotting disorders.Known or suspected breast cancer, unless that is the intended target.Known or suspected estrogen dependent tumors.

Adverse reactions

CNS

Dizziness.Headache.Mental depression.Migraine.Spasms of limb and facial muscles.

Eyes

Intolerance of contact lenses.Steepening of corneal curvature.

Gastrointestinal

Abdominal cramps.Bloating.Cholestatic jaundice.Nausea. Vomiting.

Skin

Blood eruptions from skin.Blotchy skin pigmentation. Increase of facial and body hair.Loss of scalp hair.Red skin patches from capillary congestion.

Other

Blood clotting disorders.Breast tumors.Elevated blood pressure.Fluid retention.Gall bladder disease.Increased calcium level in blood.Increased sensitivity to light.Reduced carbohydrate tolerance.

Comments

Conjugated estrogens are derived from pregnant mare urine under cruel conditions including continual confinement, continual standing with no option to lay down or turn around, restriction of drinking water, inadequate veterinary oversight, killing of the newborn or young foals, then immediate reimpregnation. The pregnancies are repeated until the mare becomes infertile or sick, at which time she is killed. This treatment has not been directly witnessed by the author. However, Redwings Horse Sanctuary, World Society for the Protection of Animals, and others have researched this issue, interviewed Wyeth-Ayerst representatives, and directly inspected the farms in question. Furthermore, Wyeth-Ayerst has aggressively blocked every attempt other drug companies have made to obtain FDA approval to sell a synthetic generic equivalent, based on the argument that those generics cannot possibly be equivalent--because they do not contain the same organic impurities.